Iovance Biotherapeutics, Inc. (IOVA) stock
IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3086% above fair value
$7.48−0.05 (-0.66%)
Close on Nov 18, 2026Market cap $3.39BP/E –Yield –
Iovance Biotherapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Iovance Biotherapeutics's gross margin for the twelve months ending Jun 30, 2026 was 48.4%. For fiscal 2025 it was 34.3%, against 43.2% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 34.3% | −8.9 |
| FY2024 | Dec 31, 2024 | 43.2% | +30.0 |
| FY2023 | Dec 31, 2023 | 13.1% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 56.1% | +37.6 |
| Q1 FY2026 | Mar 31, 2026 | 40.5% | +27.1 |
| Q4 FY2025 | Dec 31, 2025 | 50.3% | +1.6 |
| Q3 FY2025 | Sep 30, 2025 | 43.0% | −3.2 |
| Q2 FY2025 | Jun 30, 2025 | 18.5% | +19.3 |
| Q1 FY2025 | Mar 31, 2025 | 13.4% | +928.9 |
| Q4 FY2024 | Dec 31, 2024 | 48.7% | +854.3 |
| Q3 FY2024 | Sep 30, 2024 | 46.2% | +871.5 |
| Q2 FY2024 | Jun 30, 2024 | -0.8% | +760.5 |
| Q1 FY2024 | Mar 31, 2024 | -915.5% | – |
| Q4 FY2023 | Dec 31, 2023 | -805.6% | – |
| Q3 FY2023 | Sep 30, 2023 | -825.4% | – |
| Q2 FY2023 | Jun 30, 2023 | -761.3% | – |
See a number that looks wrong?